Kidney Disease, Proteinuria
Conditions
Keywords
chronic allograft nephropathy, post transplant proteinuria
Brief summary
Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive. This trial is designed to prevent a major mediator of this process, namely the expansion of the cortical interstitial compartment of the kidney where most of the scarring occurs. The drug being studied, Losartan, has proven efficacious in a number of kidney diseases.
Detailed description
Renal transplant loss due to chronic allograft nephropathy (CAN) is widely acknowledged as a major problem that has increased in relative importance as the incidence of early graft loss from acute rejection has declined. Studies from various centers, including the University of Minnesota, suggest that, after excluding patients dying with a functioning graft, as many as 80% of patients who will return to dialysis do so because of CAN. At the present time there are no therapeutic options once the clinical manifestations of CAN have developed. Testing measures to prevent CAN have not been addressed. The overall purpose of this project is to investigate the role of the renin-angiotensin-aldosterone system (RAAS) in the development of CAN. This system plays an important role in the progression of many experimental and clinical renal diseases. Furthermore, blockade of this system with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers has yielded beneficial results in retarding injury and progression in numerous intrinsic renal diseases. This study specifically investigates the long term benefit of the angiotensin II receptor blocker, losartan, in the prevention of cortical interstitial volume expansion (an accurate predictor of long term graft function) and graft loss from biopsy proven CAN in a 5 year, randomized, double masked, placebo controlled study of kidney transplant recipients. This clinical trial will directly test the hypothesis that blockade of the renin angiotensin aldosterone system will provide a substantial benefit through blood pressure lowering independent mechanisms, namely, interruption of fibrogenic pathways, anti-proteinuric actions, amelioration of hyperfiltration and possibly some immunomodulatory effects. The proposed studies will also characterize the interstitial ultrastructural compositional changes that occur in the renal allografts with CAN, the effects of treatment on these changes and provide a complete description of the incidence and predictors for the development of transplant glomerulopathy. These studies will also determine the impact of angiotensin II receptor blockade on the rate of decline of glomerular filtration rate, as well as the impact of glomerular size on the rate of graft loss from CAN, the incidence and the progression of post transplant proteinuria, the nature of the permselectivity defects responsible for the proteinuria and will also explore the association of proteinuria with graft loss from CAN. This trial will also help construct a profile for the RAAS in the transplant recipients and explore the relationship between two genes polymorphisms, ACE and TGF-Beta, and CAN. These studies should help to describe the natural history, nature and pathogenesis of CAN, elucidate early markers and predictors of this important disorder and, perhaps, define a safe and useful preventative strategy.
Interventions
DRUGLosartan 100mg
To be started within three months of transplant and continued for five years.
DRUGPlacebo
No treatment with continued follow-up for five years.
Sponsors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Merck Sharp & Dohme LLC
University of Minnesota
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years. * Recipients of a first or a second renal transplant alone or in combination with a pancreas transplantation. * Informed consent * Adequate baseline biopsy; at least 10 cortical projection fields.
Exclusion criteria
* Age \< 18 years. * Serum creatinine 2.5mg/dL. * Persistent hyperkalemia; potassium \> 5.4 mEq/L. * Known hypersensitivity to losartan or iodine allergy. * Documented renal artery stenosis by duplex ultrasonography. * Recipients of grafts from an HLA-identical sibling. * Recipients whose primary renal disease is primary hyperoxaluria,dense-deposit disease, focal segmental glomerulosclerosis or hemolytic uremic syndrome. * Women of childbearing age who wish to become pregnant and/or are unwilling to use contraceptive measures or who are pregnant. * Recipients requiring ACE inhibitors or AII blockers for a cardiovascular indication (e.g. systolic dysfunction). * Recipients who are \> 55 years old and had a history of cardiovascular disease (coronary artery disease, stroke or peripheral vascular disease).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Doubling of Interstitium or Any ESRD | Baseline to 5 years | Doubling of the interstitial or any defined ESRD (including IF/TA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD | Baseline and 5 Years Post Transplant | Number of subjects who had doubling of the interstitial or any end stage renal disease (ESRD) not attributed to interstitial fibrosis and tubular atrophy (IF/TA) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Losartan within 3 months of transplantation | 77 |
| Placebo within 3 months of transplantation | 76 |
| Total | 153 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 5 | 7 |
| Overall Study | ESRD, Non IF/TA | 1 | 3 |
| Overall Study | Withdrawal by Subject | 4 | 12 |
Baseline characteristics
| Characteristic | Losartan | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 49.4 years STANDARD_DEVIATION 11.1 | 48.0 years STANDARD_DEVIATION 13.6 | 48.7 years STANDARD_DEVIATION 12.4 |
| Cause of Native Kidney Disease Diabetes mellitus | 28 Participants | 29 Participants | 57 Participants |
| Cause of Native Kidney Disease Hypertension | 8 Participants | 2 Participants | 10 Participants |
| Cause of Native Kidney Disease Other | 28 Participants | 35 Participants | 63 Participants |
| Cause of Native Kidney Disease Polycystic kidney disease | 13 Participants | 10 Participants | 23 Participants |
| Donor Type Cadaver Donor | 24 Participants | 21 Participants | 45 Participants |
| Donor Type Live Donor | 53 Participants | 55 Participants | 108 Participants |
| Race/Ethnicity, Customized Not Available | 11 Participants | 9 Participants | 20 Participants |
| Race/Ethnicity, Customized White | 66 Participants | 67 Participants | 133 Participants |
| Sex: Female, Male Female | 30 Participants | 29 Participants | 59 Participants |
| Sex: Female, Male Male | 47 Participants | 47 Participants | 94 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 2 / 77 | 0 / 76 |
| other Total, other adverse events | 35 / 77 | 42 / 76 |
| serious Total, serious adverse events | 77 / 77 | 76 / 76 |
Outcome results
Primary
Doubling of Interstitium or Any ESRD
Doubling of the interstitial or any defined ESRD (including IF/TA)
Time frame: Baseline to 5 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Losartan | Doubling of Interstitium or Any ESRD | 6 Participants |
| Placebo | Doubling of Interstitium or Any ESRD | 12 Participants |
Secondary
Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD
Number of subjects who had doubling of the interstitial or any end stage renal disease (ESRD) not attributed to interstitial fibrosis and tubular atrophy (IF/TA)
Time frame: Baseline and 5 Years Post Transplant
Population: Number of subjects who had baseline and exit biopsy samples that could be analyzed for doubling of cortical interstitial volume expansion or graft loss from IF/TA.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Losartan | Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD | 7 Participants |
| Placebo | Number of Participants With Cortical Interstitial Volume Expansion or Any ESRD | 15 Participants |